Hemorrhage Countermeasure Evaluation Capabilities RFI DARPA-SN-26-61

The Biological Technologies Office (BTO) of the Defense Advanced Research Projects Agency (DARPA) seeks input from industry and academia regarding capabilities for providing independent verification and validation, clinical trial, and commercialization support for hemorrhage countermeasures. This Request for Information (RFI) is a preliminary step to identify potential partners capable of providing third-party assessments of safety and efficacy of potential hemorrhage countermeasures and assisting in development strategies to ensure said products transition from the laboratory to civilian and government markets after research, development, testing, and evaluation (RDT&E) efforts have ended. DARPA is particularly interested in respondents who can address all the above task domains to allow one provider to have comprehensive knowledge about the data for efficiency and to tailor commercialization and regulatory strategies.

The Biological Technologies Office (BTO) of the Defense Advanced Research Projects Agency (DARPA) seeks input from industry and academia regarding capabilities for providing independent verification and validation, clinical trial, and commercialization support for hemorrhage countermeasures. This Request for Information (RFI) is a preliminary step to identify potential partners capable of providing third-party assessments of safety and efficacy of potential hemorrhage countermeasures and assisting in development strategies to ensure said products transition from the laboratory to civilian and government markets after research, development, testing, and evaluation (RDT&E) efforts have ended. DARPA is particularly interested in respondents who can address all the above task domains to allow one provider to have comprehensive knowledge about the data for efficiency and to tailor commercialization and regulatory strategies.